Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $21.0B | $20.1B | $16.7B | $14.2B | $12.7B | $11.9B | $9.9B | $10.7B | $9.8B | $9.0B | $8.4B | $7.5B | $7.4B | $7.1B | $7.2B | $7.6B | $7.8B | $8.2B | $8.1B | $8.4B | $7.8B |
| Bruttoergebnis | $14.9B | $13.9B | $10.3B | $8.8B | $7.7B | $7.5B | $5.6B | $6.9B | $6.5B | $5.9B | $5.3B | $4.6B | $4.6B | $4.5B | $4.6B | $4.7B | $4.8B | $5.2B | $5.1B | $5.4B | $5.1B |
| Bruttomarge % | 71.2% | 69.0% | 61.3% | 62.0% | 60.8% | 62.8% | 56.2% | 64.1% | 65.9% | 64.9% | 63.7% | 61.0% | 62.2% | 63.5% | 62.9% | 61.4% | 61.3% | 63.2% | 63.2% | 64.6% | 65.0% |
| Betriebsergebnis (EBIT) | $4.6B | $4.0B | $2.6B | $2.2B | $1.8B | $1.9B | $601M | $1.7B | $1.7B | $1.5B | $1.2B | $790M | $845M | $871M | $994M | $1.1B | $1.1B | $1.3B | $1.3B | $1.2B | $1.2B |
| Operative Marge % | 21.8% | 19.8% | 15.7% | 15.3% | 14.4% | 16.2% | 6.1% | 16.0% | 17.7% | 16.9% | 14.7% | 10.6% | 11.5% | 12.2% | 13.7% | 14.7% | 13.8% | 15.9% | 16.1% | 14.1% | 15.8% |
| Jahresüberschuss | $3.7B | $2.9B | $1.9B | $1.6B | $698M | $1.0B | ($82M) | $4.7B | $1.7B | $104M | $347M | ($239M) | ($119M) | ($121M) | ($4.1B) | $441M | ($1.1B) | ($1.0B) | ($2.0B) | ($495M) | ($3.6B) |
| Nettomarge % | 17.5% | 14.4% | 11.1% | 11.2% | 5.5% | 8.8% | -0.8% | 43.8% | 17.0% | 1.1% | 4.1% | -3.2% | -1.6% | -1.7% | -56.1% | 5.8% | -13.6% | -12.5% | -25.3% | -5.9% | -45.7% |
| EBITDA | — | $5.1B | $3.9B | $3.5B | $2.7B | $2.5B | $1.5B | $2.2B | $2.6B | $2.0B | $1.2B | $360M | $433M | $721M | ($3.2B) | $1.6B | $149M | ($108M) | ($699M) | $940M | ($2.3B) |
| Ergebnis je Aktie (EPS) | $2.45 | $1.93 | $1.25 | $1.09 | $0.48 | $0.73 | $-0.06 | $3.33 | $1.19 | $0.07 | $0.25 | $-0.18 | $-0.09 | $-0.09 | $-2.89 | $0.29 | $-0.70 | $-0.68 | $-1.36 | $-0.33 | $-2.81 |
| Ausstehende Aktien (Mio.) | — | 1,494M | 1,486M | 1,464M | 1,440M | 1,434M | 1,417M | 1,411M | 1,401M | 1,393M | 1,377M | 1,341M | 1,348M | 1,341M | 1,407M | 1,519M | 1,518M | 1,508M | 1,498M | 1,487M | 1,274M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für BSX. /companies/us/BSX
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms